| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) through any online brokerage.
Other companies in Madrigal Pharmaceuticals’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Madrigal Pharmaceuticals has a consensus price target of $625.29.
The stock price for Madrigal Pharmaceuticals (NASDAQ: MDGL) is $476.91 last updated October 8, 2026 at 4:00 PM EDT.
There are no upcoming dividends for Madrigal Pharmaceuticals.
Madrigal Pharmaceuticals does not have any upcoming earnings scheduled.
There is no upcoming split for Madrigal Pharmaceuticals.
Madrigal Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
